Efficacy in Medical Technology

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that in the TASKi3 Phase 2b clinical trial in rheumatoid arthritis (RA) patients who had failed to respond to at least one biologic treatment, the group treat...

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

Pitavastatin represents important treatment option for more vulnerable populations BOSTON, June 16 /PRNewswire/ -- New data presented today showed that pitavastatin is an effective treatment for the management of dyslipidemia in elderly patients, with a similar safety and tolerability profile...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

Anti-TNF Experienced Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication or Reason for Discontinuation COPENHAGEN, June 9 /PRNewswire/ -- A new analysis demonstrated that a greater proportion of patients with moderately to severely active rh...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

Data Findings Published in June Issue of Circulation SILVER SPRING, Md. and INDIANAPOLIS, June 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR ) and Eli Lilly and Company (NYSE: LLY ) today announced the results of a pivotal 16-week study showing that a once-dail...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

First-of-its-Kind Study Demonstrates REMICADE More Likely to Maintain Steroid-Free Remission in Patients Naive to Immunomodulators and BiologicTherapy CHICAGO, June 2 /PRNewswire/ -- New long-term findings from the Phase 3b study of patients with moderately to severely active Crohn's disease...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program -- SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced the presentation of new clinical results from a Phase 1-...

Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barrett's Esophagus

Large multi-center trial conducted in a community practice setting demonstrates comparable outcomes as trials conducted in predominantly tertiary academic centers SUNNYVALE, Calif., June 1 /PRNewswire/ -- Clinical trial results presented at the Digestive Disease Week in Chicago today reveal t...

Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009

SAN MATEO¿ Calif.¿ May 28 /PRNewswire/ -- Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart ...

Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain

Results Show Superior Decrease in Pain Scores Compared to Saline PARSIPPANY, N.J., May 13 /PRNewswire/ -- Ferring Pharmaceuticals recently presented the results of a six-month safety and efficacy study demonstrating that EUFLEXXA(R) (1% sodium hyaluronate) was effective at decreasing the pai...

Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure

Data Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session; Results Published On-Line in The Lancet SAN MATEO¿ Calif.¿ March 29 /PRNewswire/ -- Corthera Inc. today announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter,...

Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms

NATICK, Mass. and ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials. SPIRIT II and SPIRIT III are pros...

Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session

SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC...

Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results

- Lead Investigator Professor John F. Thompson Presented Results at The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies in New York City - - Detailed Efficacy Data to be Presented at ASCO May 29-June 2, 2009 - KNOXVILLE, Tenn., March 16 /PRNewswire-FirstCall/...

Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study

ATLANTA, March 12 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the first human ...

Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant

-Company Provides Update on Cash Position- -Biologics License Application for Wrinkles/Nasolabial Folds Indication Expected To Be Filed Within Two Weeks- EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE ) announced today positive top-line efficacy results ...

Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia

- 31% COMPLETE RESPONSE RATE - MEDIAN SURVIVAL OF 10.5 MONTHS IN COMPLETE RESPONDERS - FINAL DATA TARGETED FOR 2009 ASH ANNUAL MEETING SOUTH SAN FRANCISCO, Calif., March 3 /PRNewswire-FirstCall/ -- Hana Biosciences (Nasdaq: HNAB ) today announced new positive preliminary efficacy ...

Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study

LYON, France, February 18 /PRNewswire-FirstCall/ -- - Global Clinical Study Program Across Dengue Endemic Regions in Latin America and Asia Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that its investigational tetr...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

PHILADELPHIA, and REHOVOT Israel, February 12 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG ) reported today the first ever in-vivo efficacy data for a systemic microRNA-based cancer therapeutic. The animal-model study demonstrated a marked suppression of a microRNA that was f...

Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures

SEATTLE, Dec. 6 /PRNewswire/ -- Phase III data on carisbamate, an investigational compound recently filed with the FDA for the adjunctive treatment of partial onset seizures (POS) in patients 16 years of age and older, was presented today during the poster sessions of the 32nd Annual Meeting of th...

Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention

Company's R&D Update Today Unveils Rich Development Pipeline of Compounds Meeting Important Medical Needs KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today revealed top-line results of a long-term Phase III clinical study of its psych...

Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections

Data to be presented at annual ICAAC/IDSA meeting in Washington, D.C. WASHINGTON, Oct. 28 /PRNewswire/ -- Scientists at NanoBio Corporation have demonstrated for the first time in humans that a novel topical treatment for cold sores (herpes labialis), NB-001, speeds healing of lesions as effe...

Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections

Iclaprim also achieved high eradication rates for the most common pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) REINACH, Switzerland, Oct. 26 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical tri...

Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay

SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM ) announced today that data presented this week demonstrated that in Pfizer Inc's (NYSE: PFE ) phase III trial of Selzentry(TM) (maraviroc) in treatment naive individuals with CCR5-tropic ...

Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)

Additional Data Presentation Shows Encouraging 12-Month Outcomes from Single- Center Study Involving Patients with Predominantly Complex Lesions WASHINGTON, Oct. 14 /PRNewswire/ -- OrbusNeich today announced that an interim analysis of 12-month follow-up data from the global e-HEALING regist...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a Repeat Procedure Compared to TAXUS(R) at Two Years WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent meta-analysis ...

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent

New coronary stent features thin struts designed for more uniform drug delivery NATICK, Mass., and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced comprehensive data from the TAXUS ATLAS clinical program,...

NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium

TOKYO and CHIPPENHAM, England, October 7 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC), announce results of two Phase II studies evaluating the efficacy, safety and tolerability of NVA237 presented at the annual...

New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study

Data from SONIC Trial Showed REMICADE Therapy is More Likely to Induce Steroid-Free Remission and Mucosal Healing Compared with Standard Immunomodulator, Azathioprine ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Data presented for the first time from the Phase 3b Study of Patie...

Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness

Results to be Presented at the North American Menopause Society 19th Annual Meeting EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) will present an abstract in a presentation on their new drug candidate, VG101, for the treatmen...

New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy

PORTO, Portugal, September 24 /PRNewswire/ -- - Novel Treatment Also Demonstrated Significant Improvement in Quality of Life and Reduction in Depressive Symptoms Positive data from three phase III studies presented today at the 8th European Congress of Epileptology, Berlin, Germany, demons...

MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma

REHOVOT, Israel and JERSEY CITY, New Jersey, September 18 /PRNewswire-FirstCall/ -- - A Collaborative Study by Scientists at the Weizmann Institute of Science and Scientists at Sheba Medical Center, With the aid of Rosetta Genomics, Demonstrated That Overexpression of miR-451 Inhibited Growth ...

Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment

Additional Analysis Shows HUMIRA Effectively Treats Adult Patients with Moderate to Severe Psoriasis Regardless of Age, Duration of Disease, Diagnosis of Psoriatic Arthritis or Recent Systemic Therapy PARIS, Sept. 18 /PRNewswire-FirstCall/ -- More psoriasis patients achieve efficacy when...

Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings

TORONTO, Sept. 16 /PRNewswire/ - In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available heparin coated catheters, both products achieved significant reductions (88%) in thrombus versus the polyurethane (Carbothane(TM)) contro...

NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect

PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced successful top-line results from the second phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met the t...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

BRIDGEWATER, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from its Phase III pivotal efficacy trial that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochl...

Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study

MUNICH, Germany, September 1 /PRNewswire-FirstCall/ -- Biosensors International Group, Ltd ("Biosensors", "Company"), (Bloomberg: BIG:SP), (Singapore:B20) today announced that a next-generation drug-eluting stent, developed by Biosensors, has demonstrated equal safety and efficacy as compared ...

Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant

Investor Conference Call to be held on Wednesday, August 6, 2008 at 8:00 a.m. EXTON, Pa., Aug. 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today positive top-line efficacy and safety results from two pivotal, Phase III clinical studies ...

Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced new data showing that its investigational drug Dimebon continues to produce broad, clinically meaningful benefits in Alzheimer's disease patients after long-term dosing, and appears to operate th...

Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus

Study Demonstrates Feasibility and Efficacy of Treating Patients with Primary Liver Cancer SAN FRANCISCO, and YONGIN-SI, South Korea, July 22 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., announ...

Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles

- Top-line Data Expected in August - EXTON, Pa., July 2 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today the completion of the pivotal efficacy portion of its Phase III clinical studies (IT-R-005/006) investigating the Isolagen Therapy(TM) for the trea...